In patients with acute coronary syndrome, decrease seen in cardiac death, MI, stent thrombosis with TiNO-coated stent, which was offset by increase in target lesion revascularization<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, May 30, 2023 (HealthDay News) — For patients with acute coronary syndrome (ACS), titanium-nitride-oxide (TiNO)-coated stents do not improve long-term outcomes in terms of a composite outcome over third-generation everolimus-eluting stents (EES), according to a study published online May 19 in JAMA Cardiology<\/em> to coincide with EuroPCR, the official annual meeting of the European Association of Percutaneous Cardiovascular Interventions, held from May 14 to 17 in Paris.<\/p>\n Frederic Bouisset, M.D., from the Cardiovascular Center Aalst in Belgium, and colleagues compared the rate of the main composite outcome of cardiac death, myocardial infarction (MI), or ischemia-driven target lesion revascularization at five years in a multicenter randomized trial involving patients with ACS with at least one de novo lesion randomly assigned to receive either a TiNO-coated stent or a third-generation EES (989 and 502 patients, respectively).<\/p>\n The researchers found that the main composite outcome events occurred in 11.2 and 12.0 percent of patients in the TiNO and EES groups, respectively (hazard ratio, 0.94 [95 percent confidence interval, 0.69 to 1.28]; P = 0.69). In the TiNO and EES arms, respectively, the rate of cardiac death was 0.9 versus 3.0 percent (hazard ratio, 0.30 [0.13 to 0.69] P = 0.005); MI was 4.6 versus 7.0 percent (hazard ratio, 0.64 [0.41 to 0.99]; P = 0.049); stent thrombosis was 1.2 versus 2.8 percent (hazard ratio, 0.43 [0.20 to 0.93] P = 0.034); and target lesion revascularization was 7.4 versus 6.4 percent (hazard ratio, 1.16 [0.77 to 1.76]; P = 0.47).<\/p>\n “A significant reduction in cardiac death, MI, and stent thromboses in favor of TiNO-coated stents was offset by numerically higher rates of ischemia-driven target lesion revascularization,” the authors write.<\/p>\n Several authors disclosed ties to pharmaceutical and medical device companies, including Hexacath, which funded the study.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n